Lupine Publishers-Journal of Hepatology Research


Advanced Hepatocellular Carcinoma in A ScottishPopulation – Current Experience and the Future by Baxter MA in Current Trends in Gastroenterologyand Hepatology in Lupine Publishers

Sorafenib is the current first line standard of care in patients with advanced hepatocellular carcinoma (HCC). Several other drugs are emerging as efficacious agents in this setting. This article will outline our current real-world experience with sorafenib in a Scottish population as well as discuss the evidence behind new potential therapies in Lupine Publishers.

For more information, please go through the below links

https://lupinepublishers.com/gastroenterology-hepatology-journal/fulltext/advanced-hepatocellular-carcinoma-in-a-scottish-population-current-experience-and-the-future.ID.000112.php

https://lupinepublishers.com/gastroenterology-hepatology-journal/pdf/CTGH.MS.ID.000112.pdf

https://lupinepublishers.com/gastroenterology-hepatology-journal/abstracts/advanced-hepatocellular-carcinoma-in-a-scottish-population-current-experience-and-the-future.ID.000112.php

For more Lupine Publishers Open Access Journals Please visit our website:http://www.lupinepublishers.com/


Comments

Popular posts from this blog

The Use of Sodium-Glucose Cotransporter 2 Inhibitors in Non-Alcoholic Fatty Liver Disease

Acute Upper Gastrointestinal Bleeding (UGIB) In A Resource Limited Setting Highly Endemic for Viral Hepatitis B: Which Etiologies for Which Real Clinical Practices?

Food Sources and Bioavailability of Calcium